These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12782574)

  • 1. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
    Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
    Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
    Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
    Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis.
    Brodie SG; Xu X; Li C; Kuo A; Leder P; Deng CX
    Oncogene; 2001 Mar; 20(12):1445-54. PubMed ID: 11313888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
    Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological prevention of a multigene cancer syndrome.
    Croci S; Nicoletti G; Landuzzi L; De Giovanni C; Astolfi A; Marini C; Di Carlo E; Musiani P; Forni G; Nanni P; Lollini PL
    Cancer Res; 2004 Nov; 64(22):8428-34. PubMed ID: 15548714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
    Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and Her-2/neu in juvenile angiofibromas.
    Schick B; Veldung B; Wemmert S; Jung V; Montenarh M; Meese E; Urbschat S
    Oncol Rep; 2005 Mar; 13(3):453-7. PubMed ID: 15706416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
    Duan W; Ding H; Subler MA; Zhu WG; Zhang H; Stoner GD; Windle JJ; Otterson GA; Villalona-Calero MA
    Oncogene; 2002 Nov; 21(51):7831-8. PubMed ID: 12420220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression in the lung of p53 mutant mice exposed to cigarette smoke.
    Izzotti A; Cartiglia C; Longobardi M; Bagnasco M; Merello A; You M; Lubet RA; De Flora S
    Cancer Res; 2004 Dec; 64(23):8566-72. PubMed ID: 15574763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
    Jochum W
    Verh Dtsch Ges Pathol; 2004; 88():224-30. PubMed ID: 16892556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inactivation of p53 in human cells does not result in aneuploidy.
    Bunz F; Fauth C; Speicher MR; Dutriaux A; Sedivy JM; Kinzler KW; Vogelstein B; Lengauer C
    Cancer Res; 2002 Feb; 62(4):1129-33. PubMed ID: 11861393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 family members in myogenic differentiation and rhabdomyosarcoma development.
    Cam H; Griesmann H; Beitzinger M; Hofmann L; Beinoraviciute-Kellner R; Sauer M; Hüttinger-Kirchhof N; Oswald C; Friedl P; Gattenlöhner S; Burek C; Rosenwald A; Stiewe T
    Cancer Cell; 2006 Oct; 10(4):281-93. PubMed ID: 17045206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice.
    Tsumura H; Yoshida T; Saito H; Imanaka-Yoshida K; Suzuki N
    Oncogene; 2006 Dec; 25(59):7673-9. PubMed ID: 16785989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.
    Hayakawa Y; Rovero S; Forni G; Smyth MJ
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9464-9. PubMed ID: 12867593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse with human mutant p53 expression in the prostate epithelium.
    Elgavish A; Wood PA; Pinkert CA; Eltoum IE; Cartee T; Wilbanks J; Mentor-Marcel R; Tian L; Scroggins SE
    Prostate; 2004 Sep; 61(1):26-34. PubMed ID: 15287091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
    Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
    Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
    Lin SC; Lee KF; Nikitin AY; Hilsenbeck SG; Cardiff RD; Li A; Kang KW; Frank SA; Lee WH; Lee EY
    Cancer Res; 2004 May; 64(10):3525-32. PubMed ID: 15150107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.